Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Receivables: 2009-2024

Historic Change in Receivables for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to $2.2 million.

  • OptimizeRx's Change in Receivables fell 17119.11% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2901.41%. This contributed to the annual value of $2.2 million for FY2024, which is 7511.76% down from last year.
  • As of FY2024, OptimizeRx's Change in Receivables stood at $2.2 million, which was down 7511.76% from $8.7 million recorded in FY2023.
  • Over the past 5 years, OptimizeRx's Change in Receivables peaked at $10.7 million during FY2020, and registered a low of -$2.3 million during FY2022.
  • For the 5-year period, OptimizeRx's Change in Receivables averaged around $5.3 million, with its median value being $7.0 million (2021).
  • Per our database at Business Quant, OptimizeRx's Change in Receivables soared by 159643.31% in 2020 and then plummeted by 13262.06% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Change in Receivables stood at $10.7 million in 2020, then plummeted by 34.43% to $7.0 million in 2021, then tumbled by 132.62% to -$2.3 million in 2022, then skyrocketed by 481.85% to $8.7 million in 2023, then crashed by 75.12% to $2.2 million in 2024.
  • Its Change in Receivables stands at $2.2 million for FY2024, versus $8.7 million for FY2023 and -$2.3 million for FY2022.